Stoke Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview

Stoke Therapeutics

04/08/2023 19:38

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 7
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report 
a 6.6% increase in revenue to $3.444 million from $3.23 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Stoke Therapeutics
Inc is
for a loss of 64 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $20​, above​ its last closing price
of $5.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.68       -0.70      -0.53     Beat    23.9
 Dec. 31 2023  -0.70       -0.70      -0.65     Beat    7.4
 Sep. 30 2022  -0.68       -0.68      -0.66     Beat    3.5​
 Jun. 30 2022  -0.69       -0.69      -0.63     Beat    8.4
 ​​Mar.        0.37        0.36       -0.66     Missed  -282.2
 31 2022                                                
 Dec. 31 2021  -0.64       -0.62      -0.66     Missed  -5.9​
 Sep. 30 2021  -0.61       -0.59      -0.61     Missed  -3.8
 Jun. 30 2021  -0.45       -0.47      -0.60     Missed  -27.7
 This summary was machine generated August 4 at 18:38 GMT.  All
figures in US dollars  unless otherwise stated